Dual antiplatelet therapy, devices, complications, and anatomical results
| No | Antiplatelet therapy | WEB (mm) | Stent | Complication* | DSA 6 †months | DSA 12 †months | WEB shape 6 months‡ | WEB shape 12 ‡months |
| 1 | Clopidogrel+aspirin | 7×5 | Acclino 3.5×25 | 0 | 1 | 1 | 0 | 0 |
| 2 | Clopidogrel+aspirin | 7×4 | LVIS JR 3.5×18 | 0 | 1 | 1 | 1 | 1 |
| 3 | Clopidogrel+aspirin | 6×3 | LVIS JR 3.5×23 | 0 | 3 | NA | 0 | NA |
| 4 | Clopidogrel+aspirin | 5×3 | LVIS JR 2.6×34 | 0 | 1 | 1 | 0 | 0 |
| 5 | Ticagrelor+aspirin | 8×3 | Enterprise 4×16 | 1 | 1 | 1 | 0 | 0 |
| 6 | Ticagrelor+aspirin | 4×3 | Enterprise 4×23 | 0 | 1 | 1 | 0 | 0 |
| 7 | Clopidogrel+aspirin | 8×3 | LVIS JR 2.5×23 | 1 | NA | NA | NA | NA |
| 8 | Ticagrelor+aspirin | 8×4 | LVIS JR 2.5×23 | 2 | 1 | 1 | 0 | 0 |
| 9 | Ticagrelor+aspirin | 9×5 | LVIS JR 2.5×17 | 0 | 1 | 1 | 0 | 0 |
| 10 | Ticagrelor+aspirin | 11×8 | LVIS JR 3.5×18 | 0 | 1 | 1 | 0 | 0 |
| 11 | Ticagrelor+aspirin | 7×3 | LVIS JR 2.5×13 | 0 | 1 | 1 | 2 | 2 |
| 12 | Ticagrelor+aspirin | 6×3 | LVIS JR 2.5×13 | 0 | NA | 1 | NA | 1 |
| 13 | Ticagrelor+aspirin | 4×2 | LVIS JR 2.5×17 | 0 | 1 | 1 | 0 | 0 |
| 14 | Ticagrelor+aspirin | 6×3 | LVIS JR 2.5×13 | 0 | 1 | 1 | 0 | 0 |
| 15 | Ticagrelor+aspirin | 3×2 | LVIS JR 2.5×13 | 0 | 1 | 1 | 0 | 0 |
| 16 | Ticagrelor+aspirin | 5×2 | LVIS JR 2.5×17 | 1 | 2 | 2 | 1 | 1 |
| 17 | Ticagrelor+aspirin | 9×6 | LVIS JR 2.5×17 | 2 | 1 | NA | 0 | NA |
| 7×3 | LVIS JR 2.5×17 | 2 | 1 | NA | 0 | NA | ||
| 6×3 | LVIS JR 2.5×23 | 2 | 1 | NA | 2 | NA |
*0: none; 1: ischemic; 2: hemorrhage.
†1: complete occlusion; 2: neck remnant; 3: aneurysm remnant.
‡0: no WEB shape modification; 1: mild WEB shape modification (<50% of decrease in height); 2: strong WEB shape modification (≥50% in height).
NA, not available.